Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPHY-SEIN antibiotic prophylaxis during breast lumpectomy
2025-525020-99-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jul 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefazolin and sodium chloride in breast cancer (2 arms), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Any surgical site infection within 30 days. Planned start Jul 2026; status: authorised.
02
Drugs
cefazolinsodium chloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-525020-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525020-99-00.